ClinicalTrials.gg
CompletedNCT00618748Updated Jul 27, 2011Results posted

Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

A Phase 3 interventional study of Olanzapine in Bipolar I Disorder, sponsored by Eli Lilly and Company. Completed at 10 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-07-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To assess the efficacy and safety of olanzapine in the long-term treatment for patients with bipolar I disorder, depressed.

Read the detailed description

This is an open-label, multi-center, long-term treatment study conducted only in Japanese sites. The subjects are patients who fulfill the diagnostic criteria for bipolar I disorder, most recent episode depressed, as defined in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) (296.50=unspecified, 296.52=moderate severity, 296.53=severe without psychotic features, 296.54=severe with psychotic features), who have completed Study HGMP (NCT#00510146) and patients who did not participate in Study HGMP who have been recruited to participate in Study HGMS.

02

Conditions studied

  • Bipolar I Disorder

Keywords

  • Bipolar
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be aged 18 to less than 75 years.
  2. Each patient must be reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and must understand the nature of the study and have provided .
  3. All female patients must test negative for pregnancy.
  4. Females of breast-feeding potential must agree not to breastfeed an infant during the study and for 1 month following the last dose of study drug.
  5. Male patients who are not surgically sterilized must agree to use a reliable method of during the study and for 1 month following the last dose of study drug.
  6. Patients must fulfill the diagnostic criteria for bipolar I disorder, most recent episode depressed, as defined in the Fourth Edition, Text Revision (DSM-IV-TR).
  7. Patients must have experienced, in the opinion of the investigator, at least one previous manic or mixed episode, as defined in the DSM-IV-TR.
  8. Patients must have a current Young Mania Rating Scale (YMRS) Total score =\<8.

Exclusion criteria

Exclusion Criteria:

  1. Is investigator site personnel directly affiliated with this study or their immediate families.
  2. Is a Lilly employee.
  3. Has previously completed or withdrawn from this study or any other study investigating olanzapine.
  4. Is pregnant or nursing.
  5. Has a serious, unstable illness such that death is anticipated within 1 year or intensive care unit hospitalization for the disease is anticipated within 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Pre-Olanzapine

    Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.

    Drug: Olanzapine

  • Experimental
    Pre-Placebo

    Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.

    Drug: Olanzapine

  • Experimental
    New Olanzapine

    Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.

    Drug: Olanzapine

Interventions

  • 5-20 mg/day, oral, daily

    Also known as: LY170053

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events Leading to Discontinuation

    An adverse event (AE) is an untoward medical event associated with the use of the study drug or study procedure, whether or not it is considered related to the study drug or study procedure. Results presented are the percentage of participants who experienced an adverse event that resulted in the discontinuation of the study.

    Time frame: Baseline through 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

Secondary outcomes

  1. Change From Baseline in Glucose and Lipid Panel at Week 24 or Week 48 Endpoint

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  2. Change From Baseline in Weight at Week 24 or Week 48 Endpoint

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  3. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint

    The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  4. Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  5. Change From Baseline in Clinical Global Improvement- Bipolar (CGI-BP) at Week 24 or Week 48 Endpoint

    CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The scores for mania, depression, and overall illness each range from 1 (normal, not ill) to 7 (very seriously ill).

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  6. Percentage of Participants With Emergence of Mania at Week 24 or Week 48

    Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  7. Percentage of Participants With High Suicidality at Week 24 or Week 48

    The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).

    Time frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  8. Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Week 24 or Week 48

    EPS symptoms measured by DIEPSS are grouped into 4 categories: Parkinsonism, akathisia, dystonia, and dyskinesia. Severity ranges from level 0 (none, normal) to 4 (severe). A participant is deemed to have EPS at endpoint if they have an abnormal endpoint. Normal baseline Parkinsonism is defined as a score not ≥3 on 1 item or ≥2 on 2 items; abnormal endpoint is a score ≥3 on 1 item or ≥2 on 2 items, or an increase of 3 on Parkinsonism total. Normal baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score ≥2 or an increase ≥2 from that baseline score.

    Time frame: 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  9. Change From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint

    HbA1c is a test that measures the amount of glycated hemoglobin in the blood over prolonged periods of time.

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  10. Change From Baseline in Prolactin at Week 24 or Week 48 Endpoint

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

  11. Change From Baseline to in QTcF at Week 24 or Week 48 Endpoint

    Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval)

    Time frame: baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)

07

Results

Posted Jun 27, 2011

Participant flow

Participant flow — Overall Study
MilestonePre-OlanzapinePre-PlaceboNew Olanzapine
Started562520
Completed45206
Not completed11514
Withdrew: Adverse event438
Withdrew: Physician decision311
Withdrew: Withdrawal by subject415

Outcome measures

PrimaryPercentage of Participants With Adverse Events Leading to Discontinuation

An adverse event (AE) is an untoward medical event associated with the use of the study drug or study procedure, whether or not it is considered related to the study drug or study procedure. Results presented are the percentage of participants who experienced an adverse event that resulted in the discontinuation of the study.

Time frame:
Baseline through 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events Leading to Discontinuation
percentage of participantsPre-OlanzapinePre-PlaceboNew Olanzapine
Percentage of Participants With Adverse Events Leading to Discontinuation7.112.040.0
SecondaryChange From Baseline in Glucose and Lipid Panel at Week 24 or Week 48 Endpoint
Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · millimole/Liter
Change From Baseline in Glucose and Lipid Panel at Week 24 or Week 48 Endpoint
millimole/LiterPre-OlanzapinePre-PlaceboNew Olanzapine
Glucose, Fasting0.03 ± 0.470.37 ± 0.550.68 ± 1.31
Cholesterol0.033 ± 0.6990.040 ± 0.7160.086 ± 1.031
Low-density lipoprotein ( LDL) Cholesterol0.141 ± 0.676-0.034 ± 0.7310.008 ± 0.855
High-density lipoprotein ( HDL) Cholesterol-0.036 ± 0.221-0.046 ± 0.212-0.074 ± 0.239
Triglycerides-0.108 ± 0.5430.485 ± 1.4150.382 ± 1.270
SecondaryChange From Baseline in Weight at Week 24 or Week 48 Endpoint
Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · kilograms
Change From Baseline in Weight at Week 24 or Week 48 Endpoint
kilogramsPre-OlanzapinePre-PlaceboNew Olanzapine
Change From Baseline in Weight at Week 24 or Week 48 Endpoint0.29 ± 2.790.92 ± 3.025.36 ± 4.34
SecondaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint

The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint
units on a scalePre-OlanzapinePre-PlaceboNew Olanzapine
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 24 or Week 48 Endpoint-0.2 ± 8.3-0.4 ± 6.5-5.8 ± 11.6
SecondaryChange From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · units on a scale
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint
units on a scalePre-OlanzapinePre-PlaceboNew Olanzapine
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 24 or Week 48 Endpoint0.4 ± 1.5-0.2 ± 1.0-0.1 ± 1.7
SecondaryChange From Baseline in Clinical Global Improvement- Bipolar (CGI-BP) at Week 24 or Week 48 Endpoint

CGI-BP is a measure of illness severity especially adapted for bipolar illness. It allows rating of mania, depression, and overall illness. The scores for mania, depression, and overall illness each range from 1 (normal, not ill) to 7 (very seriously ill).

Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Improvement- Bipolar (CGI-BP) at Week 24 or Week 48 Endpoint
units on a scalePre-OlanzapinePre-PlaceboNew Olanzapine
CGI-BP Mania-0.1 ± 0.40.1 ± 0.30.1 ± 0.2
CGI-BP Depression-0.3 ± 0.9-0.0 ± 0.9-1.1 ± 1.3
CGI-BP Overall Bipolar Illness-0.3 ± 1.0-0.1 ± 0.7-0.9 ± 1.1
SecondaryPercentage of Participants With Emergence of Mania at Week 24 or Week 48

Emergence of mania is defined as first occurrence of score of \>=15 in the YMRS total score in the post-baseline period of Acute Phase. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Number · percentage of participants
Percentage of Participants With Emergence of Mania at Week 24 or Week 48
percentage of participantsPre-OlanzapinePre-PlaceboNew Olanzapine
Percentage of Participants With Emergence of Mania at Week 24 or Week 48000
SecondaryPercentage of Participants With High Suicidality at Week 24 or Week 48

The MINI module C (MINI-C) is a rating scale for severity of suicidal thoughts and behaviors. The MINI-C is composed of 12 Yes/No questions with variable scores assigned to each question. The scale ranges from 0 to 52 with higher scores indicating a greater presence of suicidal thoughts and/or behaviors. Based upon scores, suicidality is defined as Low (1-8), Medium (9-16), and High (\>=17).

Time frame:
24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Number · percentage of participants
Percentage of Participants With High Suicidality at Week 24 or Week 48
percentage of participantsPre-OlanzapinePre-PlaceboNew Olanzapine
Percentage of Participants With High Suicidality at Week 24 or Week 483.600
SecondaryPercentage of Participants With Extra-Pyramidal Symptoms (EPS) at Week 24 or Week 48

EPS symptoms measured by DIEPSS are grouped into 4 categories: Parkinsonism, akathisia, dystonia, and dyskinesia. Severity ranges from level 0 (none, normal) to 4 (severe). A participant is deemed to have EPS at endpoint if they have an abnormal endpoint. Normal baseline Parkinsonism is defined as a score not ≥3 on 1 item or ≥2 on 2 items; abnormal endpoint is a score ≥3 on 1 item or ≥2 on 2 items, or an increase of 3 on Parkinsonism total. Normal baseline akathisia, dystonia and dyskinesia is defined as a score \<2; abnormal endpoint is a score ≥2 or an increase ≥2 from that baseline score.

Time frame:
24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Number · percentage of participants
Percentage of Participants With Extra-Pyramidal Symptoms (EPS) at Week 24 or Week 48
percentage of participantsPre-OlanzapinePre-PlaceboNew Olanzapine
Akathisia000
Dyskinesia000
Dystonia000
Parkinsonism3.605.0
SecondaryChange From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint

HbA1c is a test that measures the amount of glycated hemoglobin in the blood over prolonged periods of time.

Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · percentage of glycated hemoglobin
Change From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint
percentage of glycated hemoglobinPre-OlanzapinePre-PlaceboNew Olanzapine
Change From Baseline in Hemoglobin (HbA1c) at Week 24 or Week 48 Endpoint-0.016 ± 0.2590.036 ± 0.2430.180 ± 0.282
SecondaryChange From Baseline in Prolactin at Week 24 or Week 48 Endpoint
Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · microgram/Liter
Change From Baseline in Prolactin at Week 24 or Week 48 Endpoint
microgram/LiterPre-OlanzapinePre-PlaceboNew Olanzapine
Change From Baseline in Prolactin at Week 24 or Week 48 Endpoint-1.669 ± 10.498-0.388 ± 14.1793.383 ± 18.731
SecondaryChange From Baseline to in QTcF at Week 24 or Week 48 Endpoint

Time from electrocardiogram Q wave to the end of the T wave corresponding to electrical systole, fixed correction factor (QTcF interval)

Time frame:
baseline, 24 weeks (pre-olanzapine and pre-placebo) or 48 weeks (new olanzapine)
Reported as:
Mean · millisecond (msec)
Change From Baseline to in QTcF at Week 24 or Week 48 Endpoint
millisecond (msec)Pre-OlanzapinePre-PlaceboNew Olanzapine
Change From Baseline to in QTcF at Week 24 or Week 48 Endpoint-1.7 ± 16.6-8.5 ± 13.1-3.4 ± 13.9

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-Olanzapine—1/56 (1.8%)34/56 (60.7%)
Pre-Placebo—0/25 (0%)13/25 (52%)
New Olanzapine—1/20 (5%)20/20 (100%)
Most frequent serious events
Most frequent serious events
EventPre-OlanzapinePre-PlaceboNew Olanzapine
Pancreatitis acuteGastrointestinal disorders0/560/251/20
Cholecystitis acuteHepatobiliary disorders0/560/251/20
Depressive symptomPsychiatric disorders1/560/250/20
Most frequent other events
Showing 10 of 65
Most frequent other events
EventPre-OlanzapinePre-PlaceboNew Olanzapine
Weight increasedInvestigations3/561/2514/20
Increased appetiteMetabolism and nutrition disorders0/560/259/20
SomnolenceNervous system disorders2/560/255/20
Alanine aminotransferase increasedInvestigations1/560/254/20
Blood creatine phosphokinase increasedInvestigations0/561/254/20
NasopharyngitisInfections and infestations7/561/253/20
Decreased appetiteMetabolism and nutrition disorders1/560/253/20
HeadacheNervous system disorders4/563/252/20
IrritabilityGeneral disorders0/560/252/20
Aspartate aminotransferase increasedInvestigations1/560/252/20

Baseline characteristics

Age Continuous
Age Continuous(years)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Mean39.31 ± 10.4837.53 ± 7.6439.13 ± 9.5638.84 ± 9.61
Sex: Female, Male
Sex: Female, Male(Participants)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Female34141361
Male2211740
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
East Asian562520101
Region of Enrollment
Region of Enrollment(participants)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Japan562520101
Montgomery- Asberg Depression Rating Scale (MADRS) Total Score
Montgomery- Asberg Depression Rating Scale (MADRS) Total Score(units on a scale)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Mean8.05 ± 7.509.72 ± 6.4816.45 ± 9.0310.13 ± 8.18
Young Mania Rating Scale (YMRS) Total Score
Young Mania Rating Scale (YMRS) Total Score(units on a scale)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Mean0.38 ± 1.100.40 ± 0.760.45 ± 0.830.40 ± 0.97
Clinical Global Improvement- Bipolar (CGI-BP) - Mania
Clinical Global Improvement- Bipolar (CGI-BP) - Mania(units on a scale)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Mean1.09 ± 0.351.00 ± 0.001.00 ± 0.001.05 ± 0.26
CGI-BP - Depression
CGI-BP - Depression(units on a scale)Pre-OlanzapinePre-PlaceboNew OlanzapineTotal
Mean2.23 ± 0.952.48 ± 0.823.55 ± 1.152.55 ± 1.08

1 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 470-1168, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 270-1694, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hiroshima, 731-0501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iwate, 023-0801, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 231-0027, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 616-8421, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 332-0012, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shiga, 525-0037, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 170-0002, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamaguchi, 755-8505, Japan
09

References and documents

Publications

  • Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi M, Gomez JC. Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis. Psychiatry Clin Neurosci. 2014 Jul;68(7):498-505. doi: 10.1111/pcn.12156. Epub 2014 Mar 4. PubMed 24417745 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2008
First posted
Feb 20, 2008
Start
Feb 2008
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Results first posted
Jun 27, 2011
Last update
Jul 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00618748
First posted
Feb 20, 2008
Start date
Feb 2008
Primary completion
Sep 2010
Completion
Sep 2010
Results posted
Jun 27, 2011
Last update
Jul 27, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4599) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion